Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 267

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 267
---
-tax benefit
to him.

Mr. Carter resigned from
his position as Chief Financial Officer, effective on September 30, 2024. In connection with such resignation, Mr. Carter forfeited all
4,954 of his outstanding options.

Offer Letter with Dr. Corey

On March 28, 2024, we entered
into an employment agreement with Dr. Corey, our Chief Technology Officer and Founder (the “Corey Offer Letter”). Pursuant
to the Corey Offer Letter, Dr. Corey is entitled to an initial annual base salary of 350,000, an initial target annual incentive bonus
of 50% of Dr. Corey’s base salary, an initial equity grant, and general eligibility to participate in our employee benefit plans.

The Corey Offer Letter provides
that in the event Dr. Corey’s employment is terminated by us without “cause” or by Dr. Corey for “good reason”
(each as defined in the Corey Offer Letter) within 90 days before or within twelve months following a “change in control”
(as defined in the Corey Offer Letter) (the “Corey Change in Control Period”), then Mr. Corey will be entitled to full acceleration
of the vesting of any options to purchase shares of our common stock that are subject to time-based vesting.

The Corey Offer Letter provides
that in the event Dr. Corey’s employment is terminated by us without “cause” or by Dr. Corey for “good reason,”
Dr. Corey will be entitled to: (1) the continued payment of his then-current base salary for a period of up to six months following his
termination, and (2) if Dr. Corey timely elects COBRA health continuation, payment of COBRA premiums for continued health benefits for
up to six months following his termination.

Dr. Corey’s benefits
after termination outside of the Corey Change in Control Period are conditioned, among other things, on him complying with his post-termination
obligations under his agreement, including a one-year non-solicitation obligation, and his timely signing a general release of claims
in our favor.

Dr. Corey resigned from
his position as Chief Technology Officer, effective September 23, 2024. In connection with such resignation, Dr. Corey forfeited 4,613
of his outstanding options.

Consulting Agreement with Mr. Ehrlich

On September 30, 2024, we
entered into a consulting agreement with Chris Ehrlich (the “Ehrlich Consulting Agreement